About Optima-young trial

The most common form of breast cancer is hormone-sensitive, in which cancer cells depend on the female hormone estrogen to grow. The Optima-young trial focuses on this particular type of breast cancer, known as hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, in young women.

The aim of this trial is to show that suppression of chemotherapy in premenopausal HR+/HER2- breast cancer patients, guided by a Prosigna^® genomic test, is no less effective than standard treatment (which corresponds to chemotherapy and hormone therapy) in preventing cancer recurrence. The results of this research will enable us to better guide patients' treatment, particularly the administration of chemotherapy, and improve their quality of life.